Amicus Therapeutics, Inc. (FOLD) Financials
FOLD Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 777.9 million | 617.7 million |
2023-09-30 | 764.1 million | 630.8 million |
2023-06-30 | 730.1 million | 618.5 million |
2023-03-31 | 700.5 million | 597.9 million |
FOLD Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 1.7 million | 18.1 million |
2023-09-30 | -39.9 million | 16.5 million |
2023-06-30 | -18.3 million | 16.6 million |
2023-03-31 | -20.0 million | 34.9 million |
FOLD Net Income
No data available :(
FOLD Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 286.2 million | - | 57.2 million |
2023-09-30 | 280.3 million | - | 60.2 million |
2023-06-30 | 265.6 million | 393.4 million | 58.8 million |
2023-03-31 | 267.1 million | 392.7 million | 59.4 million |
FOLD Shares Outstanding
FOLD Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.7 million | 35.0 million | 70.2 million | - |
2023-09-30 | 1.6 million | 40.7 million | 65.7 million | - |
2023-06-30 | 2.2 million | 35.1 million | 65.8 million | - |
2023-03-31 | 1.9 million | 41.5 million | 74.2 million | - |
FOLD Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 115.1 million | 13.5 million |
2023-09-30 | 103.5 million | 9.9 million |
2023-06-30 | 94.5 million | 9.1 million |
2023-03-31 | 86.3 million | 6.9 million |
FOLD
Price: $10.40
52 week price:
Earnings Per Share: -0.51 USD
P/E Ratio: -22
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.4 million
Ebitda: -271.1 millionMarket Capitalization: 3.2 billion